Comparison of 3 Automated Immunoassays for Detection of Anti-Hepatitis A Virus Immunoglobulin M in a Tertiary Care Hospital
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Three automated immunoassay kits for anti-Hepatitis A Virus (HAV) IgM−Architect, (Abbott Laboratories, USA), Elecsys (Roche Diagnostics, Germany), and ADVIA Centaur (Siemens Healthcare Diagnostics Inc., USA)−were compared. We included 178 consecutive samples, for which an anti-HAV IgM test was requested at Seoul National University Hospital from September 2009 to January 2010. Reviewing of medical records, reverse transcription (RT)-PCR for HAV RNA, or total anti-HAV assay were performed on 16 (9.0%)samples with discrepant results. The percent agreements (kappas) of the Architect and ADVIA Centaur, Architect and Elecsys, and ADVIA Centaur and Elecsys kits were 96.6%(0.91), 96.6% (0.92), and 97.8% (0.94), respectively. Eight out of 16 discrepant samples showed gray-zone values in Architect but were nonreactive in the others. Slightly earlier seroconversion was suspected in Elecsys. The 3 assays showed comparable performances with excellent agreements in a tertiary care hospital setting.
Abstract
Three automated immunoassay kits for anti-Hepatitis A Virus (HAV) IgM−Architect, (Abbott Laboratories, USA), Elecsys (Roche Diagnostics, Germany), and ADVIA Centaur (Siemens Healthcare Diagnostics Inc., USA)−were compared. We included 178 consecutive samples, for which an anti-HAV IgM test was requested at Seoul National University Hospital from September 2009 to January 2010. Reviewing of medical records, reverse transcription (RT)-PCR for HAV RNA, or total anti-HAV assay were performed on 16 (9.0%)samples with discrepant results. The percent agreements (kappas) of the Architect and ADVIA Centaur, Architect and Elecsys, and ADVIA Centaur and Elecsys kits were 96.6%(0.91), 96.6% (0.92), and 97.8% (0.94), respectively. Eight out of 16 discrepant samples showed gray-zone values in Architect but were nonreactive in the others. Slightly earlier seroconversion was suspected in Elecsys. The 3 assays showed comparable performances with excellent agreements in a tertiary care hospital setting.
참고문헌 (9)
- Dufour DR, "Chemiluminescence assay improves specificity of hepatitis C antibody detection", Clin Chem, 49, pp.940~944 (2003)
- Hess G, "Analysis of immunoassays to detect antibodies to hepatitis A virus (anti-HAV) and anti-HAV immunoglobulin M", J Virol Methods, 51, pp.221~228 (1995)
- Wiedmann M, "Evaluation of three commercial assays for the detection of hepatitis a virus", Eur J Clin Microbiol Infect Dis, 22, pp.129~130 (2003)
- Clinical and Laboratory Standards Institute, "Assessment of laboratory tests when proficiency testing is not available; Approved guideline. 2nd ed. CLSI document, GP29-A" (2008), Clinical and Laboratory Standards Institute
- Mylonakis E, "Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches", Am J Med, 109, pp.568~576 (2000)
- Cavalier E, "False positive PTH results: an easy strategy to test and detect analytical interferences in routine practice", Clin Chim Acta, 387, pp.150~152 (2008)
- Kellar KL, "Multiplexed fluorescent bead-based immunoassays for quantitation of human cytokines in serum and culture supernatants", Cytometry, 45, pp.27~36 (2001)
- Berth M, "Prevention of assay interference in infectiousdisease serology tests done on the liaison platform", Clin Vaccine Immunol, 15, pp.891~892 (2008)
- Eisenbach C, "Recurrence of clinically significant hepatitis A following liver transplantation for fulminant hepatitis A", J Clin Virol, 35, pp.109~112 (2006)